Industry Insights

31. A New Approach For Minimizing Human Errors In Biopharmaceuticals And Medical Devices 2/3/2025

    Human errors account for many manufacturing failures, simply due to the roles in our activities and systems. Relational risk analysis (ReRA) fundamentally changes the way risks are analyzed.

32. Selecting An Off-Site GMP Storage Provider 5/8/2024

    Understanding how to select a reliable off-site storage provider will empower you to ensure the integrity and accessibility of your valuable biopharmaceutical products, materials, and samples.

33. Assessing CT-P13 SC's Impact Across Indications 3/24/2021

    This is the second article in a two-part series exploring the anticipated competitive dynamics for Celltrion’s subcutaneous (SC) infliximab bio-better, CT-P13 SC, in the U.S.The author explores how market dynamics across different autoimmune indications will drive distinct uptake of CT-P13 SC, highlighting the potential impact on TNF inhibitor competition.

34. Targeted Protein Degradation: Challenges And Opportunities 8/1/2022

    Degradation is a significantly different modality from small molecule inhibition, as PROTACs have a catalytic mode of action, event-driven pharmacology, and can target undruggable proteins with shallow pockets.

35. Cell Counting Is Growing More Important Amid Advanced Therapy's Rise 4/12/2024

    You can't improve what you don't measure. This discussion explores advances in cell counting technology and the growing number of ways it aids the biotech industry and beyond.

36. A Step Toward Using More Human-Relevant Models In Biomedical Research 3/10/2021

    Animal models are ineffective in predicting human response to many biologic medicines and vaccines and present ethical and geopolitical challenges. A paradigm shift is needed to improve drug discovery.

37. EMA Issues Draft Reflection Paper On Accelerating Biosimilar Approval 5/5/2025

    In April, the European Medicines Agency issued a draft of a new guidance document titled Reflection paper on a tailored clinical approach in biosimilar development. The public consultation runs until Sept. 30, 2025.

38. 5 Ways To Drive Lab Sustainability 7/21/2025

    Laboratories drive innovation, but their environmental impact is growing. Discover five practical tips to make your lab more sustainable to reduce waste, and support global climate goals.

39. Standardization Is Key To Building A Successful Global Business Strategy 4/15/2020

    Learn how standardized approaches to biomanufacturing can lower costs, improve outcomes, and alter the landscape of the global pharmaceutical market.

40. Delivering Macromolecules: Challenges Associated With The Delivery Of Biologic Drugs

    Developers need to look beyond the formulation of a stable drug all the way to patient compliance. Numerous pitfalls exist along the journey to bring a biologic combination product to market. This integrated solutions program can help you simplify the journey.